A large-scale clinical study has shown that higher serum IL-17A levels are independently linked to a heightened risk of mortality and major adverse kidney events (MAKE) during the hospitalization of patients with AKI in the ICU [79]. This evidence concerns the gene IL17A and acute kidney injury.